Millendo Therapeutics, Inc. OVAS Income Statement

Millendo therapeutics, inc. (OVAS)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11
Revenues
-	-	-	-	-	-	-	-	-	-	56	84	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	63	-	197	189	146	-	75	30	15	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
7,540	8,350	7,308	5,981	6,204	4,585	3,871	3,200	2,769	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs of revenues
-	-	-	-	-	-	-	-	-	-	29	274	269	1,433	1,559	1,233	1,176	1,158	940	116	35	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
-	-	-	-	-	-	-	-	-	-	4,016	4,997	5,764	4,709	4,990	5,987	5,955	4,667	3,998	4,021	5,747	7,273	5,325	4,534	4,652	7,284	3,262	2,576	2,680	2,431	1,595	1,351	946	-	404	-
Selling, general and administrative
-	-	-	-	-	-	-	-	-	-	5,056	10,751	7,129	10,947	12,612	11,210	14,454	14,572	12,909	13,067	11,046	11,016	7,074	5,061	2,998	-	3,663	3,445	-	-	-	-	-	-	-	-
Restructuring
-	-	-	-	-	-	-	-	-	-	361	1,992	1,488	5,400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
4,595	4,481	4,443	4,179	4,453	1,351	3,935	1,786	1,619	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,495	-	1,525	1,883	2,020	674	370	410
Total costs and expenses
-	-	-	-	-	-	-	-	-	-	9,462	18,014	14,650	22,489	19,161	18,430	21,585	20,397	17,847	17,204	16,828	18,289	12,399	9,595	7,650	11,013	6,925	6,021	5,175	4,209	3,120	3,234	2,966	1,440	774	410
Loss from operations
-12,135	-12,831	-11,751	-10,160	-10,657	-9,694	-7,806	-4,986	-4,388	-42,403	-9,406	-17,930	-14,587	-22,368	-18,964	-18,241	-21,439	-20,240	-17,772	-17,174	-16,813	-18,289	-12,399	-9,595	-7,650	-11,013	-6,925	-6,021	-5,175	-4,209	-3,120	-3,234	-2,966	-1,440	-774	-410
Other expenses:
Interest expense (income), net
162	172	238	313	315	-95	-54	6	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other loss
-25	-40	-119	-24	-24	-69	-31	-62	-7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-11,998	-12,699	-11,632	-9,871	-10,366	-9,858	-7,891	-5,042	-4,386	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (income) loss attributable to noncontrolling interest
-	-	-	-	-	691	-355	-196	-125	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income, net
-	-	-	-	-	-	-	-	-	-	193	186	182	-	162	161	174	-	141	101	44	-	-25	-27	-	-	34	25	18	-	-	-	-	-	-	-
Interest (expense) income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-57	-	-	-	-	-	2	-	-	-	-	-
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-3	25	-60	-82	-33	-22	-27	-51	25	-28	34	84	24	24	-10	-	-	-	-	-	-	-	-	-	-	-
Loss from equity method investment
-	-	-	-	-	-	-	-	-	-	-140	-454	-421	-371	-364	-416	-391	-385	-316	-389	-471	-668	-523	-295	-97	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-	-	-	-	-	-	-	-	-	-	-9,356	-18,173	-14,886	-22,659	-19,199	-18,518	-21,683	-20,526	-17,922	-17,490	-17,206	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense
-	-	-	-	-	-	-	-	-	-	11	13	9	-16	92	50	75	75	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common stockholders
-	-	-11,632	-9,871	-	-10,549	-7,536	-4,846	-4,261	-42,130	-9,367	-18,186	-14,895	-22,643	-19,291	-18,568	-21,758	-20,601	-17,922	-17,490	-17,206	-18,890	-12,923	-9,893	-7,814	-11,000	-6,891	-5,996	-5,157	-4,192	-3,118	-3,234	-2,966	-1,440	-774	-410
Net loss per share of common stock, basic and diluted (in USD per share)
-0.65	-0.86	-0.87	-0.74	-0.78	5.85	-10.61	-6.82	-6.00	-320.62	-0.26	-0.51	-0.42	-0.60	-0.54	-0.62	-0.80	-0.75	-0.66	-0.64	-0.65	-0.82	-0.54	-0.42	-0.41	-0.65	-0.40	-0.36	-0.39	2.32	-0.42	-2.09	-2.14	-1.33	-0.89	-0.78
Weighted-average shares of common stock outstanding, basic and diluted (in shares)
18,448	14,668	13,420	13,379	13,357	4,057	710	710	710	-105,941	35,687	35,664	35,642	35,687	35,568	30,036	27,301	27,287	27,267	27,198	26,588	24,062	23,766	23,546	19,214	17,378	17,048	16,869	13,345	12,871	7,438	1,548	1,383	1,222	979	526
Other comprehensive income (loss):
Foreign currency translation adjustment
-42	42	-17	1	-9	82	11	28	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
-12,040	-	-11,649	-9,870	-10,375	-	-7,525	-4,818	-4,242	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive income attributable to noncontrolling interest
-	-	-	-	-	-	3	4	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss attributable to Millendo Therapeutics, Inc.
-	-	-11,649	-9,870	-	-	-7,528	-4,822	-4,245	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of convertible preferred stock to redemption value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-101	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,157	-4,192	-3,118	-3,234	-2,966	-1,440	-875	-410
Net loss
-	-	-11,632	-9,871	-	-10,549	-7,536	-4,846	-4,261	-42,130	-9,367	-18,186	-14,895	-22,643	-19,291	-18,568	-21,758	-20,601	-17,922	-17,490	-17,206	-	-12,923	-9,893	-7,814	-11,000	-6,891	-5,996	-5,157	-4,192	-3,118	-3,234	-2,966	-1,440	-774	-410
Unrealized gains on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	27	10	1	-38	-31	16	163	-98	22	-93	25	-12	-16	5	-13	7	29	-27	7	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-9,340	-18,176	-14,894	-22,681	-19,322	-18,552	-21,595	-20,699	-17,900	-17,583	-17,181	-18,902	-12,939	-9,888	-7,827	-10,993	-6,862	-6,023	-5,150	-4,198	-3,118	-3,234	-2,966	-1,440	-774	-410
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,619	1,374	837	523	300	300	259	-	-	-